In ovarian cancer patients treated with cisplatin, higher serum calretinin at diagnosis or a relative serum calretinin increase during treatment were both independent predictors of platinum resistance, as well as survival [24]. The gene discussed is CALB2; the disease is ovarian carcinoma.